Alterity Therapeutics Limited (ATHE)
NASDAQ: ATHE · Real-Time Price · USD
4.470
+0.500 (12.59%)
At close: Apr 17, 2026, 4:00 PM EDT
4.630
+0.160 (3.58%)
After-hours: Apr 17, 2026, 7:37 PM EDT
Alterity Therapeutics Employees
Alterity Therapeutics had 9 employees as of June 30, 2025. The number of employees decreased by 1 or -10.00% compared to the previous year.
Employees
9
Change (1Y)
-1
Growth (1Y)
-10.00%
Revenue / Employee
$491,849
Profits / Employee
-$1,081,343
Market Cap
78.18M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 9 | -1 | -10.00% |
| Jun 30, 2024 | 10 | -1 | -9.09% |
| Jun 30, 2023 | 11 | -1 | -8.33% |
| Jun 30, 2022 | 12 | 1 | 9.09% |
| Jun 30, 2021 | 11 | -1 | -8.33% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Fortress Biotech | 101 |
| Pelthos Therapeutics | 92 |
| XBiotech | 85 |
| PMV Pharmaceuticals | 54 |
| Pliant Therapeutics | 49 |
| LeonaBio | 26 |
| NeurAxis | 24 |
| PDS Biotechnology | 24 |
ATHE News
- 2 days ago - Alterity Therapeutics Appoints Highly Experienced Biotech Executive Ann Cunningham to its Board of Directors - GlobeNewsWire
- 20 days ago - Alterity Therapeutics (ATHE) Prepares for Phase 3 Trial After FDA Feedback - GuruFocus
- 20 days ago - Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program - GlobeNewsWire
- 20 days ago - Alterity Therapeutics Gains FDA Backing For Phase 3 MSA Trial - Nasdaq
- 5 weeks ago - Alterity Therapeutics to Participate in the Bell Potter Healthcare Horizons Summit - GlobeNewsWire
- 6 weeks ago - Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments - GlobeNewsWire
- 2 months ago - Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update - GlobeNewsWire
- 5 months ago - Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference - GlobeNewsWire